CTOs on the Move

Quellis Biosciences

www.quellisbio.com

 
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Quellis Biosciences raised $17M on 12/10/2019

Similar Companies

JSR Life Sciences

JSR Life Sciences is a business unit of JSR Corporation, a global company built on more than 50 years of performance material expertise and it began research in the life sciences field more than 30 years ago. We are continually developing highly functional materials and products to meet the current and future needs of the growing biotechnology industry. Using a variety of integrated, leading-edge technologies, JSR Life Sciences provides materials that contribute to the manufacturing process of biopharmaceuticals, life science research applications, in vitro diagnostics and medical devices. JSR Life Sciences has offices, laboratories and manufacturing facilities in Tokyo and Tsukuba (JP), Sunnyvale (CA, USA), Leuven (BE) and Beijng (CN). We are a part of the JSR Corporation, an international company employing over 6’000 people worldwide and being a leading materials supplier in a variety of technology driven markets. JSR Corporation`s global network is headquartered in Tokyo (Japan) and has factories and offices all over the world. As a research-oriented organization, JSR Corporation pursues close collaborations with leading innovators in a number of industries that are key to the present and future welfare of human society: life sciences, elastomers, electronic materials, energy storage, display materials and optical materials.

Avidity Biosciences

Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.

Delix Therapeutics

Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics.

Q Bio

Our Q Exam is based on landmark systems biology research done at Stanford University. In about 75 minutes, we take blood, saliva, urine and a non-invasive whole-body scan from which we measure over 3000 clinically-relevant genetic, chemical, and anatomical biomarkers to build the world`s most comprehensive quantitative snapshot of your health at a point in time.

Sensorion

Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by a mutation of the gene encoding for otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children (GJB2-GT).